-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions, affecting up to 30% of the world's population.
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions, affecting up to 30% of the world's population.
There is conclusive evidence that NAFLD is a multi-system disease.
The clinical burden of NAFLD is not limited to serious liver-related complications (cirrhosis, liver failure or hepatocellular carcinoma), but also includes extrahepatic diseases that affect medical expenditures.
This study conducted a meta-analysis of observational studies to quantify the degree of association between NAFLD and the risk of extrahepatic cancer.
The researchers systematically searched the observational cohort studies published in PubMed, Scopus and Web of Science databases from the beginning to December 30, 2020.
NAFLD studies that have not been confirmed by biopsy are available for analysis.
Meta analysis uses random effects model.
The correlation between NAFLD and the risk of esophageal cancer The correlation between NAFLD and the risk of gastric cancer was included in 10 cohort studies, covering 182,202 middle-aged people (24.
8% with NAFLD); during an average follow-up of 5.
8 years, a total of 8485 cases of different parts of the disease occurred Extrahepatic cancer.
NAFLD is significantly associated with an increase in the risk of gastrointestinal cancer (esophageal cancer, gastric cancer, pancreatic cancer, or colorectal cancer) by nearly 1.
5-2 times.
NAFLD is associated with breast cancer risk.
In addition, NAFLD is associated with an approximately 1.
2-1.
5-fold increase in the risk of lung cancer, breast cancer, gynecological or urinary system cancer.
All risks are not related to age, gender, smoking, obesity, diabetes or other potential confounding factors.
The overall heterogeneity of most primary meta-analyses is relatively low.
The sensitivity analysis results are consistent with the above.
In summary, this large meta-analysis shows that NAFLD is related to the long-term risk of extrahepatic cancer (especially gastrointestinal cancer, breast cancer and gynecological cancer) in the median increase of 1.
2-2 times in the past 6 years.
Further research is needed to decipher the complex association between NAFLD and cancer development.
Original source: Mantovani Alessandro, Petracca Graziana, Beatrice Giorgia et al.
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
Gut, 2021, undefined: undefined.
Want to know more For information content, please click to read the original text to download the Metz Medical APP~
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions, affecting up to 30% of the world's population.
There is conclusive evidence that NAFLD is a multi-system disease.
The clinical burden of NAFLD is not limited to serious liver-related complications (cirrhosis, liver failure or hepatocellular carcinoma), but also includes extrahepatic diseases that affect medical expenditures.
This study conducted a meta-analysis of observational studies to quantify the degree of association between NAFLD and the risk of extrahepatic cancer.
The researchers systematically searched the observational cohort studies published in PubMed, Scopus and Web of Science databases from the beginning to December 30, 2020.
NAFLD studies that have not been confirmed by biopsy are available for analysis.
Meta analysis uses random effects model.
The correlation between NAFLD and the risk of esophageal cancer The correlation between NAFLD and the risk of gastric cancer was included in 10 cohort studies, covering 182,202 middle-aged people (24.
8% with NAFLD); during an average follow-up of 5.
8 years, a total of 8485 cases of different parts of the disease occurred Extrahepatic cancer.
NAFLD is significantly associated with an increase in the risk of gastrointestinal cancer (esophageal cancer, gastric cancer, pancreatic cancer, or colorectal cancer) by nearly 1.
5-2 times.
NAFLD is associated with breast cancer risk.
In addition, NAFLD is associated with an approximately 1.
2-1.
5-fold increase in the risk of lung cancer, breast cancer, gynecological or urinary system cancer.
All risks are not related to age, gender, smoking, obesity, diabetes or other potential confounding factors.
The overall heterogeneity of most primary meta-analyses is relatively low.
The sensitivity analysis results are consistent with the above.
In summary, this large meta-analysis shows that NAFLD is related to the long-term risk of extrahepatic cancer (especially gastrointestinal cancer, breast cancer and gynecological cancer) in the median increase of 1.
2-2 times in the past 6 years.
Further research is needed to decipher the complex association between NAFLD and cancer development.
Original source: Mantovani Alessandro, Petracca Graziana, Beatrice Giorgia et al.
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
Gut, 2021, undefined: undefined.
Want to know more For information content, please click to read the original text to download the Metz Medical APP~
